Valuation: Carmat SA

Market Cap 6.15M 7.03M 5.78M 5.27M 9.89M 672M 9.89M 69.32M 26.75M 343M 26.41M 25.83M 1.11B P/E 2023
-3.09x
P/E 2024 -0.95x
Enterprise Value 59.25M 67.79M 55.68M 50.81M 95.37M 6.48B 95.39M 668M 258M 3.31B 255M 249M 10.67B EV / Sales 2023
56.1x
EV / Sales 2024 13.5x
Free-Float
89.06%
Yield 2023 *
-
Yield 2024 -
Current year 0.1
Extreme 0.099
0.1
1 year 0.1
Extreme 0.0962
0.11
3 years 0.08
Extreme 0.085
9.99
5 years 0.08
Extreme 0.085
30.8
10 years 0.08
Extreme 0.085
40.06
Manager TitleAgeSince
Chief Executive Officer 55 01/09/2016
Director of Finance/CFO - 12/12/2018
Chief Tech/Sci/R&D Officer - 01/04/2025
Director TitleAgeSince
Director/Board Member 55 -
Director/Board Member 68 02/01/2017
Director/Board Member 79 20/04/2017
Date Insider Type Main position Quantity % Market Cap. Importance
13/3/25 Sell

Chairman

1,343,333 2.3347%
13/3/25 Buy

Chairman

1,343,333 2.3347%
29/5/24 Buy

Director

1,343,333 4.6122%
Change 5-day change 1-year change 3-year change Capi.($)
-.--%-.--%-9.17%-98.65% 7.08M
+0.57%-1.98%-27.05%-3.28% 105B
-0.34%-0.67%-23.64%-0.77% 11.63B
-0.66%-6.06%+90.59%+114.23% 9.52B
-0.52%+5.55%-50.01%-66.86% 4.22B
+2.40%+3.36%-24.63%+25.14% 2.39B
-5.97%-3.90%-8.71%-61.25% 2.19B
+1.53%+7.78% - - 1.96B
-0.58%+2.75%-19.33%-27.67% 1.55B
Average -0.38%+1.37%-8.99%-14.89% 15.41B
Weighted average by Cap. +0.36%-2.15%-18.85%+2.44%

Financials

2023 2024
Net sales 3.84M 4.39M 3.61M 3.29M 6.18M 420M 6.18M 43.28M 16.7M 214M 16.49M 16.13M 691M 7.34M 8.4M 6.9M 6.3M 11.82M 803M 11.82M 82.84M 31.97M 410M 31.56M 30.87M 1.32B
Net income -53.87M -61.64M -50.63M -46.2M -86.71M -5.89B -86.73M -608M -234M -3.01B -231M -226M -9.7B -51.4M -58.81M -48.3M -44.08M -82.73M -5.62B -82.75M -580M -224M -2.87B -221M -216M -9.26B
Net Debt 49.64M 56.8M 46.65M 42.57M 79.9M 5.43B 79.92M 560M 216M 2.77B 213M 209M 8.94B 53.1M 60.76M 49.91M 45.54M 85.48M 5.81B 85.49M 599M 231M 2.97B 228M 223M 9.56B
Logo Carmat SA
Carmat SA, formerly known as Carmat SAS is a France-based company engaged in the development and production of heart prosthesis. The Company is developing an orthotopic and biocompatible artificial heart which works like a natural heart, and which is hydraulically activated. It specializes in the development of a fully implantable orthotopic artificial heart, its electrical power supply system, and its telediagnosis system. The Company formed a network of partnerships with hospitals and various scientific companies, such as The Georges Pompidou European Hospital, The Marie Lannelongue Surgical Center, The Hospital Charles Nicolle of Rouen, Dedienne Sante, PaxiTech, Vignal Artru Industries, French Vessels, and Blood Institute, Laboratoire de Recherche Biochirurgicale and others.
Employees
153
  1. Stock Market
  2. Stocks
  3. ALCAR Stock
-40%: Exceptional extension
d
:
:
SEIZE THE OFFER!